Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for Ventavis, an inhaled product in-licensed from Schering AG in October 2003. (BioWorld Today)
ImmunoGen Inc. licensed certain rights to its Tumor-Activated Prodrug (TAP) technology to Centocor Inc. in a deal worth up to $43.5 million, plus royalties. (BioWorld Today)
Shares of Cellegy Pharmaceuticals Inc. sank nearly 45 percent Monday, following news late last week that the FDA issued a not approvable letter for the company's anal fissure product, Cellegesic. (BioWorld Today)
Adolor Corp. reported topline results from a Phase III study showing its postoperative ileus drug, alvimopan, failed to meet the primary endpoint in a trial meant to support a marketing authorization application in the European Union. (BioWorld Today)
Just a few weeks after completing the treatment portion of a Phase II/III trial of Fibrillex, Neurochem Inc. partnered its AA amyloidosis drug with Centocor Inc. in a deal worth up to $54 million. (BioWorld Today)
Arena Pharmaceuticals Inc. takes a case-by-case approach when it comes to partnering its drug candidates. If the economics are right, the San Diego-based company will sign on the dotted line. (BioWorld Today)
